GLOBAL BLOOD THERAPEUTICS IN (GBT)

US37890U1088 - Common Stock

68.49  +0.01 (+0.01%)

After market: 68.49 0 (0%)

Fundamental Rating

2

Overall GBT gets a fundamental rating of 2 out of 10. We evaluated GBT against 588 industry peers in the Biotechnology industry. GBT may be in some trouble as it scores bad on both profitability and health. GBT is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

GBT had negative earnings in the past year.
GBT had negative earnings in each of the past 5 years.
In the past 5 years GBT always reported negative operating cash flow.

1.2 Ratios

Industry RankSector Rank
ROA -37.05%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -127.41%
PM (TTM) -137.3%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

GBT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GBT has more shares outstanding
GBT has a worse debt/assets ratio than last year.

2.2 Solvency

GBT has an Altman-Z score of 1.24. This is a bad value and indicates that GBT is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 4.92 is on the high side and indicates that GBT has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 4.92
Debt/FCF N/A
Altman-Z 1.24
ROIC/WACCN/A
WACC10.15%

2.3 Liquidity

GBT has a Current Ratio of 6.88. This indicates that GBT is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 6.17 indicates that GBT has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 6.88
Quick Ratio 6.17

More info and screens

4

3. Growth

3.1 Past

The earnings per share for GBT have decreased strongly by -16.51% in the last year.
The Revenue has grown by 42.53% in the past year. This is a very strong growth!
EPS 1Y (TTM)-16.51%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-12.5%
Revenue 1Y (TTM)42.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q50.46%

3.2 Future

GBT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.02% yearly.
GBT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 48.11% yearly.
EPS Next Y2.94%
EPS Next 2Y18.02%
EPS Next 3Y21.63%
EPS Next 5Y9.02%
Revenue Next Year47.16%
Revenue Next 2Y50.99%
Revenue Next 3Y48.16%
Revenue Next 5Y48.11%

3.3 Evolution

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GBT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GBT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -15.98

4.3 Compensation for Growth

GBT's earnings are expected to grow with 21.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.02%
EPS Next 3Y21.63%

More info and screens

0

5. Dividend

5.1 Amount

GBT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GLOBAL BLOOD THERAPEUTICS IN

NASDAQ:GBT (10/4/2022, 7:00:01 PM)

After market: 68.49 0 (0%)

68.49

+0.01 (+0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.62B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.05%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -127.41%
PM (TTM) -137.3%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 4.92
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 6.88
Quick Ratio 6.17
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-16.51%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y2.94%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)42.53%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y